Abstract OT-33-01: Combination ipatasertib and atezolizumab to prevent recurrence in triple negative breast cancer(TNBC): A phase II single arm trial

Mapping Intimacies ◽

10.1158/1538-7445.sabcs20-ot-33-01 ◽

2021 ◽

Author(s):

Elizabeth Mittendorf ◽

Sara Tolaney ◽

Paul Wileyto ◽

Michelle DeMeo ◽

Hope Rugo ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative Breast Cancer ◽

Triple Negative

Download Full-text

A Prospective, Belgian Multi-center, Single-arm, Phase II Study of Neoadjuvant Weekly Paclitaxel and Carboplatin Followed by Dose Dense Epirubicin and Cyclophosphamide in Stage II and III Triple Negative Breast Cancer

Case Medical Research ◽

10.31525/ct1-nct04224922 ◽

2020 ◽

Author(s):

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Phase Ii Study ◽

Stage Ii ◽

Weekly Paclitaxel ◽

Download Full-text

Faculty Opinions recommendation of Multicentre phase II trial of bevacizumab combined with docetaxel-carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717985140.793472566 ◽

2013 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Phase Ii Trial ◽

Neoadjuvant Treatment ◽

Multicentre Phase

Download Full-text

A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis

Annals of Oncology ◽

10.1016/j.annonc.2021.01.065 ◽

2021 ◽

Author(s):

A. Brufsky ◽

S.B. Kim ◽

Ž. Zvirbule ◽

A. Eniu ◽

J. Mebis ◽

...

Keyword(s):

Breast Cancer ◽

Randomized Trial ◽

Phase Ii ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Locally Advanced ◽

Line Treatment ◽

Primary Analysis ◽

First Line Treatment

Download Full-text

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

Annals of Oncology ◽

10.1093/annonc/mdy517 ◽

2019 ◽

Vol 30 (3) ◽

pp. 397-404 ◽

Author(s):

S. Adams ◽

P. Schmid ◽

H.S. Rugo ◽

E.P. Winer ◽

D. Loirat ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Breast Cancer Cohort ◽

Previously Treated

Download Full-text

179P Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin for early triple-negative breast cancer: A single-arm, open-label, phase II study

Annals of Oncology ◽

10.1016/j.annonc.2021.08.460 ◽

2021 ◽

Vol 32 ◽

pp. S436

Author(s):

C. Wang ◽

Z. Liu ◽

X. Chen ◽

J. Qiao ◽

L. Li ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Phase Ii Study ◽

Open Label Phase

Download Full-text

Abstract PS11-32: Mario-3 phase II study safety run-in evaluating a novel triplet combination of eganelisib (formerly IPI-549), atezolizumab (atezo), and nab-paclitaxel (nab-pac) as first-line (1L) therapy for locally advanced or metastatic triple-negative breast cancer (TNBC)

10.1158/1538-7445.sabcs20-ps11-32 ◽

2021 ◽

Author(s):

Erika Hamilton ◽

Arielle Lee ◽

Rachel Swart ◽

Gina Newton ◽

Brenda O'Connell ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Phase Ii Study ◽

Locally Advanced ◽

Download Full-text

OT3-01-14: N0937: Phase II Trial of Brostallicin and Cisplatin in Patients with Metastatic Triple Negative Breast Cancer.

10.1158/0008-5472.sabcs11-ot3-01-14 ◽

2011 ◽

Author(s):

A Moreno-Aspitia ◽

KM Rowland ◽

H Liu ◽

DW Hillman ◽

PJ Stella ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Download Full-text

OT3-01-08: Phase II Study of S-1 Combined with Cisplatin in the First-Line Treatment of Triple Negative Breast Cancer.

10.1158/0008-5472.sabcs11-ot3-01-08 ◽

2011 ◽

Author(s):

Y Fan ◽

BH Xu

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Phase Ii Study ◽

Line Treatment ◽

First Line Treatment

Download Full-text

Abstract P1-08-34: Is it possible to predict the efficacy of a combination of cetuximab plus docetaxel in patients with operable, triple negative breast cancer (TNBC)? Final biomarker results from a phase II neoadjuvant trial

10.1158/0008-5472.sabcs13-p1-08-34 ◽

2013 ◽

Author(s):

J-M Nabholtz ◽

M-A Mouret-Reynier ◽

C Abrial ◽

M-M Dauplat ◽

N Radosevic-Robin ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative Breast Cancer ◽

Triple Negative

Download Full-text

Abstract OT1-4-04: A phase II randomized, open-label, neoadjuvant study of LCL161, an oral antagonist of inhibitor of apoptosis proteins, in combination with paclitaxel in patients with triple-negative breast cancer

10.1158/0008-5472.sabcs13-ot1-4-04 ◽

2013 ◽

Author(s):

A Lluch-Hernández ◽

A Ruiz Simon ◽

C-S Huang ◽

J Cortés Castán ◽

M Ruiz-Borrego ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Inhibitor Of Apoptosis ◽

Inhibitor Of Apoptosis Proteins ◽

Apoptosis Proteins

Download Full-text